Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This cohort study is divided into two parts: Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general research consent will be included in a prospective registry. This includes patients who undergo primary surgical resection (+/- neoadjuvant/adjuvant therapy) or following immunotherapy, regardless of response. Part A is a multicenter observational registry with both prospective and retrospective enrolment. Prospective enrolment includes eligible patients entered into the registry after activation of the study at the respective participating site. Retrospective enrolment includes eligible patients diagnosed on or after 1 January 2024 whose clinical data were generated prior to registry activation. Both prospectively and retrospectively enrolled patients contribute to the registry analyses. Part B: Active Surveillance Cohort (Surveillance Study) A subset of patients from Part A who achieve a complete or near-complete response to ICI therapy, wish to avoid surgery, and are deemed appropriate for non-operative management by a multidisciplinary tumor board are offered inclusion in a phase II surveillance study (Part B). Patients enrolled in Part B will be analysed for the primary endpoint.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Potwierdzony rozpoznaniem raka przełyku, żołądka, jelita grubego lub odbytnicy
- •Nowotór ma specjalny rodzaj defektu naprawy DNA (MMRd)
- •Nowotór nie rozprzestrzenił się na inne narządy (brak przerzutów)
- •Pacjent otrzymuje leczenie immunologiczne (ICI) jako główne leczenie
- •Dla części II badania: całkowita lub prawie całkowita odpowiedź na leczenie immunologiczne
- •Świadoma zgoda pacjenta na udział w badaniu
✗ Disqualifies
- •Historia wcześniej leczonego raka przewodu pokarmowego z nawrotem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Universitätsspital Basel
Basel, Switzerland
Spitalzentrum Biel
Biel, Switzerland
Luzerner Kantonsspital
Lucerne, Switzerland
Trial contact
Dieter Köberle, Prof. Dr. med.
Marco von Strauss und Torney, PD Dr. med.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.